| LucaVax (tertomotide) / GemVax & KAEL |
NCT05303701: GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD) |
|
|
| Not yet recruiting | 3 | 750 | NA | GV1001 Placebo, Normal saline, GV1001 1.12mg, Tertomotide 1.68mg | Samsung Pharmaceutical Co., Ltd. | Moderate to Severe Alzheimer's Disease | 12/27 | 06/28 | | |
2021-004809-40: GV1001 SC for the Treatment of Mild to Moderate Alzheimer’s Disease GV1001 SC para el tratamiento de la enfermedad de Alzheimer de leve a moderada |
|
|
| Not yet recruiting | 2 | 180 | Europe | GV1001, GV1001, Lyophilisate for solution for injection | GemVax &KAEL Co., Ltd., GemVax | Mild to Moderate (stage 4 and 5) Alzheimer's Disease Enfermedad de Alzheimer de leve a moderada (estadios 4 y 5), Alzheimer's Disease Enfermedad de Alzheimer, Diseases [C] - Nervous System Diseases [C10] | | | | |
| Active, not recruiting | 2 | 180 | Europe, US | GV1001 Placebo, Normal saline, GV1001 0.56mg, Tertomotide 0.84mg, GV1001 1.12mg, Tertomotide 1.68mg | GemVax & Kael, GemVax | Mild to Moderate Alzheimer's Disease | 04/25 | 03/26 | | |
NCT05819658: GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP) |
|
|
| Completed | 2 | 78 | RoW | GV1001 Placebo, Normal saline, GV1001 0.56mg, Tertomotide 0.84mg, GV1001 1.12mg, Tertomotide 1.68mg | GemVax & Kael | Progressive Supranuclear Palsy | 10/24 | 10/24 | | |
NCT06235775: Administration of GV1001 for the Treatment of Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL2-011 |
|
|
| Active, not recruiting | 2 | 67 | RoW | GV1001 Placebo, Normal saline, GV1001 1.12mg, Tertomotide 1.68mg | GemVax & Kael | Progressive Supranuclear Palsy | 11/25 | 12/25 | | |
NCT06625710: Evaluation of the Safety, Tolerability and PK Characteristics of GV1001 in Healthy Subjects |
|
|
| Recruiting | 1 | 56 | RoW | GV1001, Tertomotide, Placebo, Normal saline | GemVax & Kael | Neuro-Degenerative Disease | 08/25 | 12/25 | | |
